IPRAVENT Respules/Respirator solution (Ipratropium bromide)
|
|
- Stewart Blankenship
- 5 years ago
- Views:
Transcription
1 Published on: 19 Sep 2014 IPRAVENT Respules/Respirator solution (Ipratropium bromide) Composition IPRAVENT Respules Each 2 ml contains: Ipratropium Bromide BP equivalent to Ipratropium Bromide (anhydrous) 500mcg Isotonic solution q.s. IPRAVENT Respirator Solution Each 2 ml contains: Ipratropium Bromide BP 500 mcg Dosage Form Solution and respules for nebulization Description Ipratropium bromide (Synthetic quaternary ammonium compound) is an anticholinergic bronchodilator, chemically related to atropine. It is a white crystalline substance, freely soluble in water and lower alcohols, and insoluble in lipophilic solvents such as ether, chloroform, and fluorocarbons. Pharmacology Pharmacodynamics Ipratropium bromide is an anticholinergic with parasympatholytic properties. In pre-clinical studies, it appears to inhibit vagally-mediated reflexes by antagonizing the action of acetylcholine, the transmitter agent released from the vagus nerve. Anticholinergics prevent the increase in intracellular concentration of cyclic guanosine monophosphate (cyclic GMP) caused by the interaction of acetylcholine with the muscarinic receptors on bronchial smooth muscle. The bronchodilation following inhalation of ipratropium bromide is induced by local drug concentrations, sufficient for anticholinergic efficacy at the bronchial smooth muscle, and not by systemic drug concentrations. Pre-clinical and clinical evidence suggest no deleterious effect of ipratropium bromide on airway mucous secretion, mucociliary clearance, or gas exchange. The bronchodilator effect of ipratropium in the treatment of acute bronchospasm associated with asthma has been shown in studies in adults and children over 6 years of age. In most of these studies ipratropium was administered in combination with an inhaled beta 2 agonist. Pharmacokinetics
2 Absorption The therapeutic effect of ipratropium bromide is produced by local action in the airways. Therefore, time courses of bronchodilation and systemic pharmacokinetics do not run in parallel. Following inhalation, dose portions from 10 30%, depending on the formulation, device and inhalation technique, are generally deposited in the lungs. The major part of the dose is swallowed and passes through the gastrointestinal tract. Due to the negligible gastrointestinal absorption of ipratropium bromide, the bioavailability of the swallowed dose portion is only approximately 2%. This fraction of the dose does not make a relevant contribution to the plasma concentrations of the active ingredient. The portion of the dose deposited in the lungs reaches the circulation rapidly (within minutes). Limited data on total systemic bioavailability (pulmonary and gastrointestinal portions), based on renal excretion (0 24 hours) of ipratropium bromide, suggest a range of 7 28% when delivery is via a nebulizer or a metered-dose inhaler product. It is assumed that this is also a valid range for inhalation from the powder preparation. Kinetic parameters describing the distribution of ipratropium bromide were calculated from plasma concentrations after intravenous administration. A rapid biphasic decline in plasma concentrations is observed. Distribution The volume of distribution (V z ) is 338 L (~4.6 L/kg). The drug is minimally (less then 20%) bound to plasma proteins. The ipratropium ion does not cross the blood-brain barrier, consistent with the ammonium structure of the molecule. Biotransformation The half-life of the terminal elimination phase is about 1.6 hours. The mean total clearance of the drug is determined to be 2.3 L/min. The major portion of approximately 60% of the systemic available dose is eliminated by metabolic degradation, probably in the liver. The main urinary metabolites bind poorly to the muscarinic receptors and have to be regarded as ineffective. Elimination A portion of approximately 40% of the systemic available dose is cleared via urinary excretion corresponding to an experimental renal clearance of 0.9 L/min. In excretion balance studies after intravenous administration of a radioactive dose, less than 10% of the drug-related radioactivity (including the parent compound and all metabolites) is excreted via the biliary-faecal route. The dominant excretion of drug-related radioactivity occurs via the kidneys. Indications IPRAVENT Respules/IPRAVENT Respirator Solution administered either alone or with other bronchodilators, especially beta-adrenergics, is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with COPD, including chronic bronchitis and emphysema. IPRAVENT Respules/IPRAVENT Respirator Solution are indicated, when used concomitantly with inhaled beta 2 -agonists, for treatment of reversible airways obstruction as in acute and chronic asthma. Dosage And Administration The respules/ respirator solution is intended only for inhalation with suitable nebulizing devices and should not be taken orally or administered parenterally. Adults (Including the Elderly) and Children (Over 12 Years of Age) mcg, three to four times daily For the Treatment of Acute Bronchospasm
3 250 mcg three to four times until the patient is stable. Daily doses exceeding 2 mg in adults and children over 12 years of age should only be given under medical supervision. Children (6 12 Years of Age) 250 mcg; up to a total daily dose of 1 mg Children (0 5 Years of Age) For the Treatment of Acute Asthma Only mcg; up to a total daily dose of 1 mg Ipratropium bromide should be administered no more frequently than 6-hourly in children less than 5 years of age. For acute bronchospasm, repeated doses may be administered until the patient is stable. Where co-administration is required, IPRAVENT Respules/IPRAVENT Respirator Solution may be combined with a short-acting, beta 2 -agonist in the same nebulizer chamber. The solution should be used as soon as possible after mixing and any unused solution should be discarded. Contraindications Ipratropium bromide is contraindicated in known or suspected cases of hypersensitivity to ipratropium bromide, or to atropine and its derivatives. Warnings And Precautions Use of the nebulizer solution should be subject to close medical supervision during initial dosing. Caution is advocated in the use of anticholinergic agents in patients predisposed to or with narrow-angle glaucoma, or with prostatic hyperplasia or bladder-outflow obstruction. As patients with cystic fibrosis may be prone to gastro-intestinal motility disturbances, ipratropium bromide, as with other anticholinergics, should be used with caution in these patients. Immediate hypersensitivity reactions following the use of ipratropium bromide have been demonstrated by rare cases of urticaria, angioedema, rash, bronchospasm, oropharyngeal oedema and anaphylaxis. There have been isolated reports of ocular complications (i.e. mydriasis, increased intra-ocular pressure, narrow-angle glaucoma, eye pain) when aerosolised ipratropium bromide, either alone or in combination with an adrenergic beta 2 - agonist, has come into contact with the eyes during nebulizer therapy. Eye pain or discomfort, blurred vision, visual halos or coloured images in association with red eyes from conjunctival congestion and corneal oedema may be signs of acute narrow-angle glaucoma. Should any combination of these symptoms develop, treatment with miotic drops should be initiated and specialist advice sought immediately. Patients must be instructed in the correct administration of IPRAVENT Respules/IPRAVENT Respirator Solution. Care must be taken not to allow the solution or mist to enter the eyes. It is recommended that the nebulized solution is administered via a mouthpiece. If this is not available and a nebulizer mask is used, it must fit properly. Patients who may be predisposed to glaucoma should be warned specifically to protect their eyes. As with other inhalation therapy, inhalation induced bronchoconstriction may occur with an immediate increase in wheezing after dosing. This should be treated straight away with a fast-acting inhaled bronchodilator. IPRAVENT Respules/IPRAVENT Respirator Solution should be discontinued immediately, the patient assessed and, if necessary, alternative treatment instituted. Drug Interactions There is evidence that the administration of ipratropium with beta-adrenergic drugs and xanthine preparations may
4 produce an additive bronchodilatory effect. The risk of acute glaucoma in patients with a history of narrow-angle glaucoma may be increased when nebulised ipratropium bromide and beta 2 -agonists are administered simultaneously. Pregnancy Pregnancy Category B. No adequate or well-controlled studies have been conducted in pregnant women. Because animal reproduction studies are not always predictive of human response, ipratropium bromide should be used during pregnancy only if clearly needed. Lactation It is not known whether ipratropium bromide is excreted in human milk. Although lipid-insoluble quaternary bases pass into breast milk, it is unlikely that the active component, ipratropium bromide, would reach the infant to an important extent, especially when inhaled. However, because many drugs are excreted in human milk, caution should be exercised when ipratropium bromide is administered to a nursing mother. Undesirable Effects Many of the listed undesirable effects can be assigned to the anticholinergic properties of ipratropium. As with all inhalation therapy, IPRAVENT Respules/IPRAVENT Respirator Solution may show symptoms of local irritation. Adverse drug reactions were identified from data obtained in clinical trials and pharmacovigilance during post approval use of the drug. The most common non-respiratory adverse reactions reported in clinical trials are headache, nausea (with or without vomiting) dryness of the mouth. The common adverse effects ( 1/100 < 1/10) include: nervous system disorders (headache), respiratory, thoracic and mediastinal disorders (cough, throat irritation), gastro-intestinal disorders [dryness of mouth, nausea and disturbances in gastrointestinal motility (diarrhoea, constipation, and vomiting). The uncommon adverse effects ( 1/1,000 < 1/100) include: immune system disorders (Urticaria), eye disorders Accommodation disturbances, narrow-angle glaucoma, cardiac disorders (Tachycardia), respiratory, thoracic and mediastinal disorders (spasm of the larynx), skin and subcutaneous disorders (Exanthema. The rare adverse effects ( 1/10,000 < 1/1000) seen include: immune system disorders (anaphylactic reaction, hypersensitivity, angioedema of tongue, lips & face), eye disorders (Increased intraocular pressure, pain in the eyes, mydriasis), cardiac disorders (Palpitations, supraventricular tachycardia, atrial fibrillation. Respiratory, thoracic and mediastinal disorders (Bronchospasms induced by the inhalation) the risk of urinary retention may be increased in patients with preexisting urinary outflow tract obstruction. If case of any side effects, talk to your doctor or pharmacist or write to drugsafety@cipla.com. You can also report side effects directly via the National Pharmacovigilance Programme of India by calling on By reporting side effects, you can help provide more information on the safety of this product. Overdosage Palpitation and increase in heart rate have been produced with inhaled doses of 5 mg. Side effects have not been caused by single inhaled doses of 2 mg in adults and 1 mg in children. Single oral doses of 30 mg of ipratropium bromide caused anticholinergic side effects, but these did not require treatment. Severe overdose is characterized by atropine-like symptoms like tachycardia, tachypnea, high fever and central effects like restlessness, confusion and hallucinations. These symptoms should be treated symptomatically. The use of
5 physostigmine is not recommended because of worsening of cardiotoxic symptoms and induction of convulsions. Packaging Information IPRAVENT Respules 500mcg. available as respule of 2 ml IPRAVENT Respirator Solution 500mcg...Bottle of 15 ml Last Updated: July 2018 Last Reviewed: July 2018 IPRAVENT Respules/Respirator solution Source URL:
IPRAVENT Rotacaps (Ipratropium bromide)
Published on: 10 Jul 2014 IPRAVENT Rotacaps (Ipratropium bromide) Composition IPRAVENT Rotacaps Each capsule contains: Ipratropium Bromide BP, equivalent to Ipratropium Bromide (anhydrous) 40 mcg Excipient..q.s.
More informationPRODUCT INFOMATION APO-IPRATROPIUM SOLUTION
PRODUCT INFOMATION APO-IPRATROPIUM SOLUTION NAME OF THE MEDICINE Ipratropium bromide. Chemical Name: (1R,3r,5S,8r)-3-[[(2RS)-3-Hydroxy-2-phenylpropanoyl]oxy]-8-methyl-8-(1- methylethyl)-8-azoniabicyclo[3.2.1]octane
More informationPRODUCT INFORMATION. IPRAVENT Inhalation Solution Unit Dose NAME OF THE MEDICINE DESCRIPTION. Ipratropium Bromide BP
PRODUCT INFORMATION IPRAVENT Inhalation Solution Unit Dose NAME OF THE MEDICINE Ipratropium Bromide BP Ipratropium bromide is a quaternary isopropyl derivative of atropine. Its chemical name is (1R, 3r,
More informationPRODUCT INFORMATION. IPRAVENT Inhalation Solution Multi Dose NAME OF THE MEDICINE DESCRIPTION PHARMACOLOGY. Ipratropium Bromide BP
PRODUCT INFORMATION IPRAVENT Inhalation Solution Multi Dose NAME OF THE MEDICINE Ipratropium Bromide BP Ipratropium bromide is a quaternary isopropyl derivative of atropine. Its chemical name is (1R, 3r,
More informationATROVENT Metered Aerosol (CFC-free)
NAME OF THE DRUG ATROVENT Metered Aerosol (CFC-free) Atrovent metered aerosol contains the active ingredient ipratropium bromide. DESCRIPTION Ipratropium bromide is a synthetic quaternary ammonium compound,
More informationDeveloped By Name Signature Date
Patient Group Direction 2156 version 2.0 Administration of Ipratropium 250mcg/ml Nebuliser Solution in Acute Asthma by Registered Practitioners employed by Torbay and South Devon NHS Foundation Date of
More informationCOMBIVENT Metered Aerosol Boehringer
COMBIVENT Metered Aerosol Boehringer Composition 1 metered dose contains: (8r)-3*-Hydroxy-8-isopropyl-1*,5*-tropanium bromide (±)-tropate monohydrate (= ipratropium bromide monohydrate) 21 mcg equivalent
More informationATROVENT NASAL and ATROVENT NASAL FORTE PRODUCT INFORMATION
ATROVENT NASAL and ATROVENT NASAL FORTE PRODUCT INFORMATION DESCRIPTION Approved Name Chemical Name Ipratropium bromide (1R, 3r, 5S, 8r)-8-Isopropyl-3-( tropoyloxytropanium bromide. C 20 H 30 NO 3 Br.
More information7.2 Part VI.2 Elements for a Public Summary
7.2 Part VI.2 Elements for a Public Summary 7.2.1 Part VI.2.1 Overview of disease epidemiology Chronic obstructive pulmonary disease (COPD) is characterized by persistent airflow limitation that is usually
More informationDUOLIN Respules (Levosalbutamol sulphate + Ipratropium bromide)
Published on: 10 Jul 2014 DUOLIN Respules (Levosalbutamol sulphate + Ipratropium bromide) Composition DUOLIN Respules Each 2.5 ml unit-dose vial contains: Levosalbutamol sulphate.1.25 mg Ipratropium bromide
More informationDUOLIN Rotacaps (Levosalbutamol sulphate + Ipratropium bromide)
Published on: 19 Sep 2014 DUOLIN Rotacaps (Levosalbutamol sulphate + Ipratropium bromide) Composition DUOLIN Rotacaps Each capsule contains: Levosalbutamol sulphate 100 mcg Ipratropium bromide.. 40 mcg
More informationTIOVA Inhaler (Tiotropium bromide)
Published on: 18 Sep 2014 TIOVA Inhaler (Tiotropium bromide) Composition TIOVA Inhaler Each actuation delivers: Tiotropium Bromide Monohydrate IP equivalent to Tiotropium... 9 mcg Suspended in propellant
More informationVENTOLIN RESPIRATOR SOLUTION
VENTOLIN RESPIRATOR SOLUTION Salbutamol QUALITATIVE AND QUANTITATIVE COMPOSITION VENTOLIN Respirator Solution contains 5mg salbutamol, as sulphate, per ml of solution and is supplied in 10 ml bottles.
More informationSummary of Product Characteristics
1 NAME OF THE MEDICINAL PRODUCT Summary of Product Characteristics Combivent UDVs 500 micrograms/2.5mg per 2.5ml Nebuliser Solution 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 2.5ml single dose unit
More informationAtrovent HFA (ipratropium bromide HFA) Inhalation Aerosol
ATTENTION PHARMACIST: Detach "Patient's Instructions for Use" from package insert and dispense with the product. Atrovent HFA (ipratropium bromide HFA) Inhalation Aerosol For Oral Inhalation Only Rx only
More informationCombivent Unit Dose Vials
Combivent Unit Dose Vials Composition 1 unit-dose vial (2.5 ml) solution for inhalation contains: Ipratropium bromide corresponding to 0.5 mg ipratropium bromide anhydrous 0.52 mg Salbutamol sulphate corresponding
More informationASTHALIN Respules (Salbutamol sulphate)
Published on: 28 Jan 2016 ASTHALIN Respules (Salbutamol sulphate) Composition Each 2.5 ml respule contains: Salbutamol Sulphate IP equivalent to Salbutamol IP. 2.5 mg Normal saline solution.q.s. Dosage
More informationASTHALIN Respirator Solution (Salbutamol sulphate)
Published on: 28 Jan 2016 ASTHALIN Respirator Solution (Salbutamol sulphate) Composition Each 1 ml contains: Salbutamol Sulphate IP equivalent to Salbutamol IP.. 5 mg Dosage Form Solution for inhalation
More informationPRODUCT INFORMATION. Ammonium chloride is an expectorant that has an irritant effect on mucous membranes.
PRODUCT INFORMATION BENADRYL Original Oral Liquid (New Formula) Name of the Medicine Diphenhydramine hydrochloride Ammonium chloride The chemical name for diphenhydramine hydrochloride is 2-(diphenylmethoxy)-N,Ndimethylethanamine
More informationPACKAGE INSERT TEMPLATE FOR SALBUTAMOL TABLET & SALBUTAMOL SYRUP
PACKAGE INSERT TEMPLATE FOR SALBUTAMOL TABLET & SALBUTAMOL SYRUP Brand or Product Name [Product name] Tablet 2mg [Product name] Tablet 4mg [Product name] Syrup 2mg/5ml Name and Strength of Active Substance(s)
More information14 41 minutes Vd 218 t ½ 22 to 70 Clearance hours Protein Binding 71%, active metabolite 42% Bioavailability 3%
Brand Name: Yupelri Generic Name: revefenacin Manufacturer: Mylan Drug Class: Anticholinergic Uses: Labeled Uses: inhalation solution for maintenance treatment of COPD 1 Unlabeled Uses: no off-label indications
More informationSalapin: Salbutamol BP 2mg as sulphate in each 5mL of a raspberry cola flavoured, sugar free syrup.
Salapin Salbutamol Syrup 2mg/5mL Qualitative and quantitative composition Salapin: Salbutamol BP 2mg as sulphate in each 5mL of a raspberry cola flavoured, sugar free syrup. Clinical particulars Therapeutic
More informationUtibron Neohaler. (indacaterol, glycopyrrolate) New Product Slideshow
Utibron Neohaler (indacaterol, glycopyrrolate) New Product Slideshow Introduction Brand name: Utibron Neohaler Generic name: Indacaterol, glycopyrrolate Pharmacological class: Long-acting beta2- agonist
More informationCore Safety Profile. Pharmaceutical form(s)/strength: Sterile eye drops 1%, 2% Date of FAR:
Core Safety Profile Active substance: Carteolol Pharmaceutical form(s)/strength: Sterile eye drops 1%, 2% P - RMS: SK/H/PSUR/0002/002 Date of FAR: 16.03.2012 4.1 THERAPEUTIC INDICATIONS Ocular hypertension
More informationFLOMIST Aqueous Nasal Spray (Fluticasone propionate)
Published on: 10 Jul 2014 FLOMIST Aqueous Nasal Spray (Fluticasone propionate) Composition FLOMIST Aqueous Nasal Spray Each spray delivers: Fluticasone Propionate BP...50 mcg Fluticasone Propionate BP...
More informationAtrovent Administration
Atrovent Administration ICEMA Training 2007 Sherri Shimshy RN OBJECTIVES Describe the pharmacology of Atrovent Identify the indications for use of Atrovent in the Adult Population Identify the indications
More informationNEW ZEALAND DATA SHEET SEREVENT Accuhaler
NEW ZEALAND DATA SHEET SEREVENT Accuhaler Salmeterol xinafoate (50 mcg per inhalation) Presentation SEREVENT Accuhaler is a moulded plastic device containing a foil strip with 60 regularly placed blisters
More informationPharmaceutical form(s)/strength: Solution: 5 mg/ml Suspensions: 2.5 and 5 mg/ml P-RMS:
0BCore Safety Profile Active substance: Betaxolol eyedrops Pharmaceutical form(s)/strength: Solution: 5 mg/ml Suspensions: 2.5 and 5 mg/ml P-RMS: HU/H/PSUR/0010/002 Date of FAR: 20.03.2013 4.2 Posology
More informationCore Safety Profile. Pharmaceutical form(s)/strength: Dry Powder Inhaler, Nebuliser Suspension, pressurised Metered Dose Inhaler (pmdi)
Core Safety Profile Active substance: Budesonide Pharmaceutical form(s)/strength: Dry Powder Inhaler, Nebuliser Suspension, pressurised Metered Dose Inhaler (pmdi) P - RMS: DK/H/PSUR/0041/001 Date of FAR:
More informationA COPD medication delivery device option: an overview of the NEOHALER
A COPD medication delivery device option: an overview of the NEOHALER 2017 Sunovion Pharmaceuticals Inc. All rights reserved 9/17 RESP019-17 Indication and Boxed Warning INDICATION ARCAPTA NEOHALER (indacaterol)
More informationPRESCRIBING INFORMATION WITH CONSUMER INFORMATION MYDRIACYL. tropicamide ophthalmic solution, USP. 0.5% and 1% w/v.
PRESCRIBING INFORMATION WITH CONSUMER INFORMATION Pr MYDRIACYL tropicamide ophthalmic solution, USP 0.5% and 1% w/v Anticholinergic Alcon Canada Inc. 2665 Meadowpine Blvd. Mississauga, ON L5N 8C7 www.alcon.ca
More informationComposition Each ml of Ventol solution for inhalation contains 5 mg Salbutamol (as sulphate).
VENTOL Composition Each ml of Ventol solution for inhalation contains 5 mg Salbutamol (as sulphate). Respiratory Solution Action Salbutamol is a short-acting, relatively selective beta2-adrenoceptor agonist.
More informationGlaxoSmithKline. Renal impairment. Hepatic impairment
RELENZA GlaxoSmithKline Zanamivir QUALITATIVE AND QUANTITATIVE COMPOSITION Each RELENZA ROTADISK consists of four regularly spaced double foil blisters each containing a white to off-white micronised powder
More informationNausicalm solution for injection is a clear colourless solution, presented in 1 ml ampoules.
Nausicalm Cyclizine lactate 50 mg/ml solution for injection Presentation Nausicalm solution for injection is a clear colourless solution, presented in 1 ml ampoules. Uses Actions Cyclizine is a piperazine
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Otrivin Comp 0.5 mg/ml + 0.6 mg/ml nasal spray, solution 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml contains 0.5 mg xylometazoline
More informationRespiratory Pharmacology. Manuel Otero Lopez Department of Anaesthetics and Intensive Care Hôpital Européen Georges Pompidou, Paris, France
Respiratory Pharmacology Manuel Otero Lopez Department of Anaesthetics and Intensive Care Hôpital Européen Georges Pompidou, Paris, France Programme Bronchomotor tone Drugs and factors influencing airway
More informationChronic obstructive pulmonary disease (COPD) is a progressive,
INFORMATION for the PHARMACIST This article was sponsored by Boehringer Ingelheim Pharmaceuticals, Inc. Improving Lung Function (FEV 1 ) in COPD Through Appropriate Counseling on Use of Inhaled Medications
More informationSUMMARY OF PRODUCT CHARACTERISTICS Version: March 2006
SUMMARY OF PRODUCT CHARACTERISTICS Version: March 2006 1. NAME OF THE MEDICINAL PRODUCT FAVINT 18 microgram, inhalation powder, hard capsule 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains
More informationChapter 7. Anticholinergic (Parasympatholytic) Bronchodilators. Mosby items and derived items 2008, 2002 by Mosby, Inc., an affiliate of Elsevier Inc.
Chapter 7 Anticholinergic (Parasympatholytic) Bronchodilators Clinical Indications for Use Indication for anticholinergic bronchodilator COPD maintenance Indication for combined anticholinergic and β-agonist
More informationCetirizine Proposed Core Safety Profile
Cetirizine Proposed Core Safety Profile Posology and method of administration Elderly subjects: data do not suggest that the dose needs to be reduced in elderly subjects provided that the renal function
More informationPROSTIGMIN (neostigmine bromide)
PROSTIGMIN (neostigmine bromide) TABLETS DESCRIPTION: Prostigmin (neostigmine bromide), an anticholinesterase agent, is available for oral administration in 15 mg tablets. Each tablet also contains gelatin,
More informationPRODUCT MONOGRAPH. (ipratropium bromide/fenoterol hydrobromide) NEBULIZER SOLUTION
PRODUCT MONOGRAPH Pr Duovent UDV (ipratropium bromide/fenoterol hydrobromide) NEBULIZER SOLUTION Each plastic unit dose vial (UDV) contains a total of 0.5 mg of ipratropium bromide and 1.25 mg fenoterol
More informationM0BCore Safety Profile
M0BCore Safety Profile Active substance: Aciclovir Pharmaceutical form(s)/strength: Tablets 200, 400 or 800 mg Dispersible tablets 200, 400 or 800 mg Oral suspensions 200 mg or 400 mg per 5 ml. Freeze
More informationMEDICATION GUIDE ANORO ELLIPTA
MEDICATION GUIDE ANORO ELLIPTA [a-nor oh e-lip-ta] (umeclidinium and vilanterol inhalation powder) for oral inhalation What is the most important information I should know about ANORO ELLIPTA? ANORO ELLIPTA
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Date: May 02, 2005
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS Date: May 02, 2005 SPCBerodualRespimat 1 1. NAME OF THE MEDICINAL PRODUCT Berodual Respimat 20/50 microgram/dose, solution for inhalation 2. QUALITATIVE AND QUANTITATIVE
More informationGlycopyrronium Bromide and Neostigmine Metilsulfate 0.5mg/2.5mg per ml
New Zealand Datasheet Glycopyrronium Bromide and Neostigmine Metilsulfate 0.5mg/2.5mg per ml Solution for injection Glycopyrronium bromide 0.5 mg/ml & Neostigmine metilsulfate 2.5 mg/ml Presentation is
More informationReference ID: Page 1
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use COMBIVENT RESPIMAT safely and effectively. See full prescribing information for COMBIVENT RESPIMAT.
More informationOXYSPAS Tablets (Oxybutynin chloride)
Published on: 10 Jul 2014 OXYSPAS Tablets (Oxybutynin chloride) Composition OXYSPAS-2.5 Tablets Each uncoated tablet contains Oxybutynin chloride... 2.5 mg OXYSPAS-5 Tablets Each uncoated tablet contains
More informationNew Zealand Datasheet
New Zealand Datasheet 1 PRODUCT NAME Asthalin 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Salbultamol respiratory solution 3 PHARMACEUTICAL FORM Asthalin is a plastic ampoule presentation containing a sterile,
More informationPRODUCT MONOGRAPH. (salbutamol sulphate and ipratropium bromide Nebulizer Solution)
PRODUCT MONOGRAPH Pr TEVA-COMBO STERINEBS (salbutamol sulphate and ipratropium bromide Nebulizer Solution) Each Unit Dose Vial (UDV) contains 0.50 mg of ipratropium bromide (as ipratropium bromide monohydrate)
More informationSummary of Product Characteristics
1 NAME OF THE MEDICINAL PRODUCT Salbuvent 5 mg/2.5 ml Nebuliser Solution Summary of Product Characteristics 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ampoule contains 5mg salbutamol (as sulphate).
More informationNEW ZEALAND DATA SHEET. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each metered dose contains terbutaline sulphate 250 µg.
NEW ZEALAND DATA SHEET 1. PRODUCT NAME BRICANYL TURBUHALER, Inhalation powder, 250 µg/dose 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each metered dose contains terbutaline sulphate 250 µg. For a full
More informationSUMMARY OF PRODUCT CHARACTERISTICS. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each sachet contains the following active ingredients:
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Lacrofarm, powder for oral solution, sachet 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each sachet contains the following active ingredients:
More informationRESPIRATORY PHARMACOLOGY - ASTHMA. Primary Exam Teaching - Westmead ED
RESPIRATORY PHARMACOLOGY - ASTHMA Primary Exam Teaching - Westmead ED Sympathomimetic agents MOA: relax airway smooth muscle and inhibit broncho constricting mediators from mast cells May also inhibit
More information1. NAME OF THE MEDICINAL PRODUCT. Vicks Sinex, 0.5 mg/ml, nasal spray solution 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
1. NAME OF THE MEDICINAL PRODUCT Vicks Sinex, 0.5 mg/ml, nasal spray solution 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Oxymetazoline hydrochloride 0.5 mg/ml 1 spray (50 l) contains approximately 25
More informationSEROBID Inhaler (Salmeterol xinafoate)
Published on: 10 Jul 2014 SEROBID Inhaler (Salmeterol xinafoate) Composition Each actuation delivers: Salmeterol (as Salmeterol Xinafoate IP) 25 mcg Suspended in propellant HFA 134a.....q.s. Dosage Form
More informationOXIS TURBUHALER 4.5 µg/dose and 9 µg/dose ASTRAZENECA
10-14 OXIS TURBUHALER 4.5 µg/dose and 9 µg/dose ASTRAZENECA formoterol fumarate dihydrate Inhalation powder Composition Each delivered dose (i.e. the dose leaving the mouthpiece) from Oxis Turbuhaler contains
More informationNew Zealand Data Sheet
New Zealand Data Sheet ATROPT EYE DROPS Atropine Sulfate Presentation ATROPT EYE DROPS contains atropine Sulfate (1%) in a sterile aqueous base. A clear, or almost clear, slightly viscous, colourless liquid
More informationBRICANYL INJECTION. terbutaline sulfate PRODUCT INFORMATION
BRICANYL INJECTION terbutaline sulfate PRODUCT INFORMATION NAME OF THE MEDICINE Terbutaline sulfate, 2-(tert-butylamino)-1-(3,5-dihydroxyphenyl) ethanol sulfate, a sympathomimetic bronchodilator with a
More informationPRODUCT MONOGRAPH. Ipratropium Bromide (as Monohydrate) and Salbutamol (as Salbutamol Sulfate) Nebulizer Solution
PRODUCT MONOGRAPH Pr COMBIVENT UDV Ipratropium Bromide (as Monohydrate) and Salbutamol (as Salbutamol Sulfate) Nebulizer Solution Each Unit Dose Vial (UDV) contains 0.50 mg of ipratropium bromide (as ipratropium
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Lacrofarm Junior, powder for oral solution, sachet 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each sachet of contains the following active
More informationPRODUCT INFORMATION VENTOLIN DISKS
PRODUCT INFORMATION VENTOLIN DISKS APPROVED NAME: Salbutamol sulphate B.P. PHYSICAL AND CHEMICAL CHARACTERISTICS: Salbutamol sulphate is a white or almost white odourless powder. It is soluble in 4 parts
More informationPackage Insert. D-Bright
Package Insert D-Bright Product Summary 1. Name of the medicinal product D-Bright 2. Qualitative and quantitative composition Each ml contains Cholecalciferol (Vitamin D3) IP 400 IU in a flavoured syrupy
More informationHistory & Development
RSPT 2317 Anticholinergic Bronchodilators () History & Development Prototypical parasympatholytic agent is atropine an alkaloid found naturally in the plants Atropa belladona (nightshade) and Datura species
More informationLACIPIL QUALITATIVE AND QUANTITATIVE COMPOSITION
LACIPIL lacidipine QUALITATIVE AND QUANTITATIVE COMPOSITION Lacidipine, 2 mg - round shaped white engraved on one face. Lacidipine, 4 mg - oval white with break line on both faces. Lacidipine, 6 mg - oval
More informationChemical name: di[(rs)-2-(1,1-dimethyl)ethylamino-1-[4-hydroxy-3- (hydroxymethyl)phenyl]ethanol] sulphate
Product Information Page 1 PRODUCT INFORMATION SALBUTAMOL SANDOZ 2.5MG/2.5ML, 5MG/2.5ML INHALATION AMPOULES NAME OF THE MEDICINE Generic name: Salbutamol sulphate BP Chemical name: di[(rs)-2-(1,1-dimethyl)ethylamino-1-[4-hydroxy-3-
More informationIpratrin uni-dose Ipratrin Adult uni-dose contains the active ingredient ipratropium bromide Consumer Medicine Information
Ipratrin uni-dose Ipratrin Adult uni-dose contains the active ingredient ipratropium bromide Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about Ipratrin
More informationPATIENT INFORMATION INCRUSE ELLIPTA
PATIENT INFORMATION INCRUSE ELLIPTA [IN-cruise e-lip-ta] (umeclidinium inhalation powder) for oral inhalation What is INCRUSE ELLIPTA? INCRUSE ELLIPTA is an anticholinergic medicine. Anticholinergic medicines
More informationPackage leaflet: Information for the patient. / / 30 mg/5 ml syrup. Ambroxol hydrochloride
Package leaflet: Information for the patient / / 30 mg/5 ml syrup Ambroxol hydrochloride Read all of this leaflet carefully before you start taking this medicine because it contains important information
More informationMUCINAC 600 Tablets (Acetylcysteine)
Published on: 10 Jul 2014 MUCINAC 600 Tablets (Acetylcysteine) Composition MUCINAC 600 Tablets Each effervescent tablet contains: Acetylcysteine 600 mg Dosage Form Oral Tablet Pharmacology Pharmacodynamics
More informationPRODUCT INFORMATION. 2-(dimethylamino) ethyl (RS)-2-(1-hydroxycyclopentyl)-2- phenylacetate hydrochloride
PRODUCT INFORMATION MINIMS CYCLOPENTOLATE EYE DROPS NAME OF THE MEDICINE Cyclopentolate hydrochloride Structural formula: Chemical name: Molecular formula: Molecular weight: 327.9 2-(dimethylamino) ethyl
More informationPackage leaflet: Information for the patient Tranexamic acid 100 mg/ml Solution for Injection tranexamic acid
Package leaflet: Information for the patient Tranexamic acid 100 mg/ml Solution for Injection tranexamic acid Read all of this leaflet carefully before you are given this medicine because it contains important
More informationPRODUCT MONOGRAPH SPIRIVA. Tiotropium Capsules for Oral Inhalation (18 μg tiotropium per capsule as tiotropium bromide monohydrate)
PRODUCT MONOGRAPH Pr SPIRIVA Tiotropium Capsules for Oral Inhalation (18 μg tiotropium per capsule as tiotropium bromide monohydrate) Capsules to be used only with the supplied HandiHaler inhalation device
More informationNEW ZEALAND DATA SHEET
NEW ZEALAND DATA SHEET NAME OF MEDICINE OXIS TURBUHALER Eformoterol fumarate dihydrate (6 µg per inhalation) PRESENTATION OXIS TURBUHALER is a multidose, inspiratory flow driven, metered dose, dry powder
More informationCOMBIVENT UDV Product Monograph Page 35 of 39
PART III: CONSUMER INFORMATION Pr Combivent UDV Ipratropium Bromide (as Monohydrate) and Salbutamol (as Salbutamol Sulfate) Nebulizer Solution Read this carefully before you start taking COMBIVENT UDV
More informationContinence PGD transdermal oxybutynin Kentera patch 36mg
Continence PGD transdermal oxybutynin Kentera patch 36mg Patient group direction for the supply of transdermal oxybutynin Kentera patch 36mg to patients suffering from urinary frequency, urgency or incontinence
More informationCHESTON PLUS Syrup (Ambroxol hydrochloride + Terbutaline sulphate + Guaiphenesin)
Published on: 22 Sep 2014 CHESTON PLUS Syrup ( hydrochloride + sulphate + ) Composition Each 5 ml contains: hydrochloride... 15 mg sulphate IP...1.25 mg IP...50 mg Menthol IP...1 mg Flavoured syrup base...
More informationFURAMIST Nasal Spray (Fluticasone furoate )
Published on: 21 Jan 2016 FURAMIST Nasal Spray (Fluticasone furoate ) Composition Each spray contains: Fluticasone furoate 27.5 mcg Dosage Form Aqueous intranasal spray Pharmacology Pharmacodynamics Fluticasone
More informationDrugs acting on the respiratory tract
Drugs acting on the respiratory tract Antiasthmatic drugs Asthma Asthma is a chronic inflammatory disease characterized by episodes of reversible airways obstruction due to bronchial hyperresponsiveness;
More informationPage 1 of 23. Reference ID:
1 HIGHLIGHTS OF PRESCRIBING INFORMATION 38 Paradoxical bronchospasm: Discontinue TUDORZA 2 39 PRESSAIR and consider other treatments if 3 These highlights do not include all the 40 paradoxical bronchospasm
More informationSUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT ALVERINE Mayoly Spindler, 60 mg hard capsules 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 60 mg of alverine citrate.
More informationPRESCRIBING INFORMATION. IPRATROPIUM BROMIDE NASAL SOLUTION, 0.03% Nasal Spray. Only
PRESCRIBING INFORMATION IPRATROPIUM BROMIDE NASAL SOLUTION, 0.03% Nasal Spray Only DESCRIPTION The active ingredient in ipratropium bromide nasal solution is ipratropium bromide monohydrate. It is an anticholinergic
More informationIMPORTANT: PLEASE READ
IMPORTANT: PLEASE READ PART III: CONSUMER INFORMATION Pr Spiriva Respimat Tiotropium Bromide Monohydrate Inhalation Solution Read this carefully before you start taking SPIRIVA RESPIMAT and each time you
More information11/2011. Revised: 03/2012 WARNINGS AND PRECAUTIONS Not for acute use: Not for use as a rescue medication (5.1)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use SPIRIVA HandiHaler safely and effectively. See full prescribing information for SPIRIVA HandiHaler.
More informationAgreed Core Safety Profile for Budesonide nasal spray suspension and Budesonide nasal powder
CSP Drug Budesonide Substance Date 13 Oct 2011 rev 11Nov Supersedes 18 Aug 2011 Agreed Core Safety Profile for DK/H/PSUR/0041/001 TABLE OF CONTENTS PAGE TITLE PAGE... 1 TABLE OF CONTENTS... 2 Introduction...
More information2. QUALITATIVE AND QUANTITATIVE COMPOSITION
NEW ZEALAND DATA SHEET 1. PRODUCT NAME MYDRIACYL (Tropicamide) 0.5% MYDRIACYL (Tropicamide) 1.0% Eye Drops 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of Mydriacyl Eye Drops contains the active
More information2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Compound Macrogol 13.72 g powder for oral solution 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each sachet of Compound Macrogol 13.72 g
More informationNEW ZEALAND DATA SHEET
1 PRODUCT NAME BISOLVON CHESTY FORTE Bromhexine hydrochloride tablets Bromhexine hydrochloride Oral Solution 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet of Bisolvon Chesty Forte contains bromhexine
More informationActive ingredients: Metoclopramide Hydrochloride mg Equivalent to metoclopramide hydrochloride anhydrous mg
Name Primperan 10 mg / 2 ml Metoclopramide hydrochloride anhydrous Solution for I.M. or I.V. injection (Ampoules) Composition Each 2 ml ampoule contains: Active ingredients: Metoclopramide Hydrochloride.
More informationMigraleve, Migraleve Pink and Migraleve Yellow Product Information
Migraleve, Migraleve Pink and Migraleve Yellow Product Information Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard Adverse events should also
More informationMOVICOL Junior Powder for Solution (macrogol 3350)
MOVICOL Junior Powder for Solution (macrogol 3350) Product Name: MOVICOL Junior Product Description: Each sachet of MOVICOL Junior contains: Macrogol 3350 Sodium chloride Sodium bicarbonate Potassium chloride
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Fexofenadine Cipla 120 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 120 mg fexofenadine
More informationNAPHCON-A Eye Drops naphazoline hydrochloride 0.025% and pheniramine maleate 0.3%.
NEW ZEALAND DATA SHEET 1. PRODUCT NAME NAPHCON-A Eye Drops naphazoline hydrochloride 0.025% and pheniramine maleate 0.3%. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Naphcon-A contains naphazoline hydrochloride
More informationAUSTRALIAN PRODUCT INFORMATION APO-BETAHISTINE (BETAHISTINE DIHYDROCHLORIDE) 2 AND 3 QUALITATIVE AND QUANTITATIVE COMPOSITION AND PHARMACEUTICAL FORM
AUSTRALIAN PRODUCT INFORMATION APO-BETAHISTINE (BETAHISTINE DIHYDROCHLORIDE) 1 NAME OF THE MEDICINE Betahistine dihydrochloride. 2 AND 3 QUALITATIVE AND QUANTITATIVE COMPOSITION AND PHARMACEUTICAL FORM
More informationPRODUCT MONOGRAPH. Indacaterol (as maleate)/glycopyrronium (as bromide) inhalation powder hard capsules. 110 mcg/50 mcg per capsule
PRODUCT MONOGRAPH Pr ULTIBRO BREEZHALER Indacaterol (as maleate)/glycopyrronium (as bromide) inhalation powder hard capsules 110 mcg/50 mcg per capsule ULTIBRO BREEZHALER capsules to be used only with
More information- COPD treatment - Eklira 400 μg Genuair 30 doses Eklira 400 μg Genuair 60 doses < Inhaled aclidinium bromide>
Kyorin Pharmaceutical Co., Ltd. 1 June 2016 (4nd version) Standard Commodity Classification No. of Japan 872259 Storage Stored at room temperature - COPD treatment - Eklira 400 μg Genuair 30 doses Eklira
More informationAVIOMARIN 50 mg tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER AVIOMARIN 50 mg tablets DIMENHYDRINATE This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine, which outlines
More informationNursing Process Focus: Patients Receiving Salmeterol (Serevent)
Prior to administration: Assess for presence/history of chronic asthma, exercise induced asthma, acute asthma attacks, and acute upper airway obstruction. Assess respiratory rate and lung sounds, pulse
More informationAtrovent Metered Aerosol (CFC Free)
Atrovent Metered Aerosol (CFC Free) Ipratropium bromide Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about Atrovent Metered Aerosol. It does not contain
More informationMOVICOL Liquid Orange Flavour Concentrate for Oral Solution (macrogol 3350)
MOVICOL Liquid Orange Flavour Concentrate for Oral Solution (macrogol 3350) NAME OF THE MEDICINE: MOVICOL Liquid Orange Flavour, Concentrate for Oral Solution. DESCRIPTION: A clear colourless solution.
More information